September 30, 2024 TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction...
October 8, 2024 Flexible approaches to eCOA administration in clinical trials: The site perspective Estelle Haenel, Celeste A. Elash, Katie Garner, Megan Turner, Scottie KernAbstract Electronic Clinical Outcome Assessment (eCOA) C
July 29, 2024 A Modern Curriculum for Training Scientists in Model-Informed Drug Development: Progress Report on FDA Grant to Train Regulatory Scientists C-Path and experienced private sector partners collaborated with global health organizations to create didactic video materials...
June 12, 2024 Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study over 12 months Digital measures may provide objective, sensitive, real-world measures of disease progression in Parkinson’s disease (PD).
May 28, 2024 Accelerating healthcare innovation: the role of Artificial intelligence and digital health technologies in critical path institute’s public-private partnerships Artificial Intelligence (AI) and Digital Health Technologies (DHTs) are radically transforming drug development. The FDA and EMA..
April 22, 2024 Unlocking the Capabilities of Large Language Models for Accelerating Drug Development Recent breakthroughs in natural language processing (NLP), particularly in large language models (LLMs), offer substantial...
December 21, 2023 Flexible approaches to eCOA administration in clinical trials: The site perspective
December 14, 2023 Best Practice Recommendations for Electronic Clinical Outcome Assessment Data Changes
November 30, 2023 Assessing asthma symptoms in children: qualitative research supporting the development of the Pediatric Asthma Diary-Child (PAD-C) and Pediatric Asthma Diary-Observer (PAD-O).
November 21, 2023 Successfully Navigating the Valley of Death: the Importance of Accelerators in Drug Discovery and Development
